4.2 Article

Identification of diphtheria toxin R domain mutants with enhanced inhibitory activity against HB-EGF

期刊

JOURNAL OF BIOCHEMISTRY
卷 157, 期 5, 页码 331-343

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jb/mvu079

关键词

cancer; CRM197; diphtheria toxin; EGF receptor; HB-EGF

资金

  1. Ministry of Education, Culture, Sports, Science and Technology of Japan [23240126, 26250033]
  2. Grants-in-Aid for Scientific Research [26250033, 24118001, 24570212, 23240126, 15K07046, 23570227, 24118008] Funding Source: KAKEN

向作者/读者索取更多资源

Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a ligand of EGF receptor, is involved in the growth and malignant progression of cancers. Cross-reacting material 197, CRM197, a non-toxic mutant of diphtheria toxin (DT), specifically binds to the EGF-like domain of HB-EGF and inhibits its mitogenic activity, thus CRM197 is currently under evaluation in clinical trials for cancer therapy. To develop more potent DT mutants than CRM197, we screened various mutant proteins of R domain of DT, the binding site for HB-EGF. A variety of R-domain mutant proteins fused with maltose-binding protein were produced and their inhibitory activity was evaluated in vitro. We found four R domain mutants that showed much higher inhibitory activity against HB-EGF than wild-type (WT) R domain. These R domain mutants suppressed HB-EGF-dependent cell proliferation more effectively than WT R domain. Surface plasmon resonance revealed their higher affinity to HB-EGF than WT R domain. CRM197(R460H) carrying the newly identified mutation showed increased cell proliferation inhibitory activity and affinity to HB-EGF. These results suggest that CRM197(R460H) or other recombinant proteins carrying newly identified mutation(s) in the R domain are potential therapeutics targeting HB-EGF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据